Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11606-024-09178-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Furocyst on Lipid Profile and Insulin Resistance Across Different Categories of Body Mass Index in Women With Polycystic Ovarian Syndrome (PCOS).
Cureus
November 2024
Centre for Advanced Research, King George's Medical University, Lucknow, IND.
Introduction Insulin resistance is a fundamental factor in the pathogenesis of polycystic ovarian syndrome (PCOS) and has been found to mediate a close association with obesity and dyslipidemia. While the anti-diabetic and anti-inflammatory properties of fenugreek seed extracts have been demonstrated, research on its anti-hyperlipidemic properties is still in its novice stage, with inconclusive evidence. The present study assessed the impact of fenugreek seed extracts rich in furostanolic saponins (Furocyst) on lipid profiles across different categories of body mass index (BMI) in women with PCOS.
View Article and Find Full Text PDFEndoscopic management of obesity and metabolic diseases.
Trends Endocrinol Metab
November 2024
Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts and Harvard Medical School, Boston, MA 02115, USA. Electronic address:
Obesity has become a global pandemic that is associated with a range of metabolic disorders. Traditional treatment options, such as lifestyle modification and anti-obesity medications, often exhibit limited efficacy and can lead to long-term weight gain, especially upon discontinuation of the medication. Although bariatric surgery is effective, its accessibility is constrained, and only a small percentage of eligible patients receive this intervention.
View Article and Find Full Text PDFA systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
CNS Spectr
November 2024
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Objective: Many psychotropic drugs are highly associated with related weight gain. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established anti-obesity and glucose-lowering agents. Preliminary evidence also indicates they are fit for purpose in mitigating psychotropic drug-related weight gain (PDWG).
View Article and Find Full Text PDFEligibility for Anti-Obesity Medications Among Medicare Beneficiaries with Overweight or Obesity.
J Gen Intern Med
October 2024
Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA.
Anti-obesity treatment preferences of healthcare providers and people living with obesity: A survey-based study.
Clin Obes
February 2025
Market Access, Novo Nordisk, Ipsos, London, UK.
A cross-sectional, online survey was conducted in the United Kingdom, France, Germany, and the United States (14 November-22 December 2022) to investigate preferences for anti-obesity medication (AOM) among people with obesity (PwO) and healthcare providers (HCPs). Eligibility: Adult PwO who self-defined their body type as overweight/obese, were trying to lose weight and had BMI ≥30.0 or 27.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!